Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
REGN

REGN - Regeneron Pharmaceuticals Inc Stock Price, Fair Value and News

980.50USD+15.61 (+1.62%)Delayed
Watchlist

Market Summary

USD980.50+15.61
Delayed
1.62%

REGN Alerts

  • 8 major insider sales recently.
  • JPMORGAN CHASE & CO reported owning 6.7% of REGN [2024-01-25]
  • JPMORGAN CHASE & CO reported owning 6.7% of REGN [2024-01-25]

REGN Stock Price

View Fullscreen

REGN RSI Chart

REGN Valuation

Market Cap

104.2B

Price/Earnings (Trailing)

26.36

Price/Sales (Trailing)

7.95

EV/EBITDA

22.05

Price/Free Cashflow

22.69

REGN Price/Sales (Trailing)

REGN Profitability

EBT Margin

32.01%

Return on Equity

15.22%

Return on Assets

11.95%

Free Cashflow Yield

4.41%

REGN Fundamentals

REGN Revenue

Revenue (TTM)

13.1B

Rev. Growth (Yr)

0.58%

Rev. Growth (Qtr)

2.13%

REGN Earnings

Earnings (TTM)

4.0B

Earnings Growth (Yr)

-3.13%

Earnings Growth (Qtr)

15.06%

Breaking Down REGN Revenue

Last 7 days

-0.6%

Last 30 days

1.6%

Last 90 days

18.2%

Trailing 12 Months

25.1%

How does REGN drawdown profile look like?

REGN Financial Health

Current Ratio

5.69

Debt/Equity

0.08

Debt/Cashflow

2.32

REGN Investor Care

Buy Backs (1Y)

0.56%

Diluted EPS (TTM)

34.77

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202312.4B12.7B13.1B13.1B
202216.5B14.2B13.5B12.2B
20219.2B12.4B13.5B16.1B
20207.0B7.4B7.9B8.5B
20196.6B6.5B6.6B6.6B
20186.1B6.2B6.4B6.7B
20175.0B5.2B5.5B5.9B
20164.4B4.6B4.7B4.9B
20153.1B3.4B3.8B4.1B
20142.3B2.5B2.6B2.8B
20131.6B1.7B1.9B2.1B
2012565.4M762.0M1.1B1.4B
2011467.7M459.7M456.5M445.8M
2010407.8M433.7M422.2M459.1M
2009273.7M308.9M344.1M379.3M
2008000238.5M

Tracking the Latest Insider Buys and Sells of Regeneron Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 15, 2024
yancopoulos george
acquired
69,030,500
399
172,723
bd. co-chair, president & cso
Feb 15, 2024
yancopoulos george
sold (taxes)
-117,894,000
953
-123,601
bd. co-chair, president & cso
Feb 14, 2024
van plew daniel p
sold
-9,831,730
942
-10,434
evp & general mgr, industrial
Feb 09, 2024
sing george l
acquired
206,665
413
500
-
Feb 09, 2024
sing george l
sold
-477,500
955
-500
-
Feb 09, 2024
fenimore christopher r.
sold
-4,689,320
953
-4,919
svp finance & cfo
Feb 09, 2024
van plew daniel p
sold (taxes)
-23,735,800
951
-24,941
evp & general mgr, industrial
Feb 09, 2024
van plew daniel p
acquired
13,382,500
378
35,375
evp & general mgr, industrial
Feb 08, 2024
sing george l
acquired
206,665
413
500
-
Feb 08, 2024
sing george l
sold
-472,500
945
-500
-

1–10 of 50

Which funds bought or sold REGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 22, 2024
SIERRA SUMMIT ADVISORS LLC
new
-
1,010,910
1,010,910
0.30%
Feb 22, 2024
Scarborough Advisors, LLC
new
-
1.00
1.00
-%
Feb 22, 2024
Dodge & Cox
reduced
-0.22
126,627,000
2,079,510,000
1.32%
Feb 21, 2024
V-Square Quantitative Management LLC
added
68.89
297,168
667,500
0.12%
Feb 21, 2024
Raleigh Capital Management Inc.
added
137
10,104
16,688
0.01%
Feb 20, 2024
Pacific Center for Financial Services
sold off
-
-11.00
-
-%
Feb 20, 2024
Able Wealth Management LLC
new
-
1,757
1,757
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
new
-
403,000
403,000
0.03%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-67.62
-1,194,390,000
630,659,000
0.09%
Feb 16, 2024
Sanibel Captiva Trust Company, Inc.
new
-
4,512,650
4,512,650
0.17%

1–10 of 44

Are Funds Buying or Selling REGN?

Are funds buying REGN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own REGN
No. of Funds

Unveiling Regeneron Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
8.25%
8,838,240
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 09, 2024
capital world investors
4.8%
5,194,729
SC 13G/A
Jan 25, 2024
jpmorgan chase & co
6.7%
7,219,436
SC 13G/A
Jan 25, 2024
jpmorgan chase & co
6.7%
7,219,436
SC 13G/A
Jan 25, 2024
blackrock inc.
8.1%
8,629,707
SC 13G/A
Feb 13, 2023
capital world investors
5.9%
6,315,819
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
8.15%
8,722,448
SC 13G/A
Feb 03, 2023
blackrock inc.
8.6%
9,166,817
SC 13G/A

Recent SEC filings of Regeneron Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Feb 23, 2024
144
Notice of Insider Sale Intent
Feb 22, 2024
144
Notice of Insider Sale Intent
Feb 22, 2024
144
Notice of Insider Sale Intent
Feb 20, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 14, 2024
144
Notice of Insider Sale Intent
Feb 13, 2024
4
Insider Trading
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
4
Insider Trading
Feb 12, 2024
4
Insider Trading

What is the Fair Value of REGN?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Regeneron Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.8B
6.8B
-16.59% -47.80%
-7.82
5.38
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.9B
1.8B
-23.99% -31.71%
-45.13
10.87
76.23% 61.08%
17.2B
2.3B
-4.89% -18.90%
116.89
7.44
15.05% 75.21%
13.6B
3.7B
-7.62% -26.87%
22.76
3.68
8.87% 75.42%
MID-CAP
8.1B
272.9M
-2.06% 34.31%
-13.4
29.75
141.38% 4.43%
6.0B
-
-3.85% 226.12%
-9.54
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.34
6.44
23.54% 31.53%
3.9B
240.7M
-19.08% -10.99%
-13.19
16.26
-1.03% -92.09%
3.7B
270.6M
8.92% 47.81%
-15.63
13.81
440.80% -27.84%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
24.15
4.3
81.69% -7.29%
629.6M
1.0B
-9.17% -57.89%
-1.15
0.6
-43.15% 58.48%
179.0M
4.9M
-14.18% -58.18%
-1.09
36.62
-57.57% 50.48%
114.7M
881.7K
289.54% 381.25%
-2.42
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Regeneron Pharmaceuticals Inc News

Latest updates
MarketBeat4 hours ago
Seeking Alpha21 Feb 202412:13 pm

Regeneron Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue2.1%3,4343,3633,1583,1623,4142,9362,8972,8572,9654,9523,4535,1392,5292,4232,2941,9521,8281,8641,7441,5781,373
Costs and Expenses9.3%2,4612,2522,1422,2152,2681,713-1,7471,7072,3121,6061,7911,4161,2561,2411,2961,1281,1881,0051,262893
  S&GA Expenses15.2%738641652601661529-476450560445415406304327348367452304295291
  R&D Expenses9.5%1,1771,0751,0851,1011,043911-794844738665714743657685722584552526886486
EBITDA Margin-3.5%0.36*0.37*0.41*0.41*0.43*0.50*0.49*0.47*0.57*0.60*0.62*0.61*0.51*0.48*0.47*0.47*0.40*0.41*0.37*0.35*0.41*
Interest Expenses2.8%18.0018.0019.0018.0017.0015.00-13.0014.0014.0014.0014.0015.0015.0026.0010.006.007.008.008.008.00
Income Taxes-111.7%-12.0010311540.00128194-11188.0027418465413875.0015622.0044.0098.0099.0032.0085.00
Earnings Before Taxes3.3%1,1481,1111,0838581,3251,510-9631,0612,5031,8173,7531,2531,225998919669890769225546
EBT Margin-4.2%0.32*0.33*0.38*0.37*0.40*0.47*0.47*0.45*0.55*0.58*0.59*0.58*0.48*0.45*0.44*0.44*0.36*0.37*0.33*0.32*0.38*
Net Income15.1%1,1601,0089688181,1971,316-8529742,2291,6323,0991,1151,149842897625792670193461
Net Income Margin-1.1%0.30*0.30*0.34*0.34*0.36*0.42*0.42*0.40*0.48*0.50*0.52*0.50*0.44*0.41*0.40*0.40*0.33*0.32*0.32*0.32*0.37*
Free Cashflow-2.2%1,0901,1141,0221,3681,7206295645642,1022,3733,4146276691,231-254943698787557188897
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets2.9%33,08032,16330,65830,06029,21527,67827,20626,34925,43523,67221,48617,77217,16316,08414,42915,75814,80513,93913,17412,85511,735
  Current Assets4.5%19,47918,63516,92316,90915,88415,42915,53014,30614,01513,77513,33810,0559,7799,0987,8608,6447,6897,1096,6516,9296,448
    Cash Equivalents27.2%2,7382,1521,9373,9163,1063,4913,3953,3462,8983,4322,0721,4382,1941,5731,9922,2081,6301,3851,0461,7091,480
  Inventory0.7%2,5812,5622,5082,4252,4022,4122,2191,9921,9512,0541,9842,1651,9171,8021,6411,4811,4161,3441,3171,2091,151
  Net PPE------3,7043,6383,5563,4823,3963,3593,2633,2223,1383,0312,9452,8902,7712,6772,6132,576
Liabilities-2.1%7,1077,2596,6406,5656,5516,2396,5186,4346,6666,4146,3595,7956,1385,9595,3713,6253,7163,4353,4183,4102,977
  Current Liabilities-4.9%3,4233,5993,1043,1003,1412,8793,0343,0083,9333,7153,7323,2182,6972,3383,7022,0552,0971,7651,7131,5111,443
  Long Term Debt-100.0%-1,9831,9821,9821,9811,9811,9811,9801,9801,9801,9791,9791,9791,978-------
    LT Debt, Non Current0.0%1,9831,9831,9821,9821,9811,9811,9811,9801,9801,9801,9791,9791,9791,978-------
Shareholder's Equity4.3%25,97324,90424,01823,49522,66421,43920,68819,91518,76917,25815,12711,97711,02510,1269,05712,13311,09010,5049,7569,4458,757
  Retained Earnings4.4%27,26026,10125,09324,12523,30722,11020,79419,94218,96816,73915,10712,00810,8939,7448,9028,0047,3806,5885,9185,7255,254
  Additional Paid-In Capital0.9%11,35411,25210,88910,5989,9499,5189,1208,7548,0887,9197,2266,8886,7166,5936,2635,2114,4294,3884,2644,1613,912
Shares Outstanding-100.0%-106107107107107108107106106105105108108110110109109109109108
Float-------62,000---57,065---63,344---32,929--
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-2.2%1,0901,1141,0221,3681,7206295642,1022,3733,4146276691,231-254943698787557188897729
  Share Based Compensation17.9%240204202239232166160167188137146131122101104106134117106108127
Cashflow From Investing86.7%-66.20-496-2,386-235-1,857192-413-1,705-2,012-2,438126-1,059-305-7751,453-443-208-207-836-776-265
Cashflow From Financing-9.5%-446-407-614-322-247-725-10165.00-906385-118-366-305612-2,612336-345-11.00-15.30120-83.00
  Buy Backs-44.8%2805077236944289133943528551912893243601005,07233624719.00-10.00-

REGN Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues:   
Revenue from contract with customer$ 13,117.2$ 12,172.9$ 16,071.7
Expenses:   
Research and development4,439.03,592.52,860.1
Acquired in-process research and development186.1255.148.0
Selling, general, and administrative2,631.32,115.91,824.9
Other operating (income) expense, net(2.1)(89.9)(45.6)
Total expenses9,070.17,434.07,124.9
Income from operations4,047.14,738.98,946.8
Other income (expense):   
Other income (expense), net225.2179.3436.3
Interest expense(73.0)(59.4)(57.3)
Total other income (expense)152.2119.9379.0
Income before income taxes4,199.34,858.89,325.8
Income tax expense245.7520.41,250.5
Net income$ 3,953.6$ 4,338.4$ 8,075.3
Net income per share - basic (in dollars per share)$ 37.05$ 40.51$ 76.40
Net income per share - diluted (in dollars per share)$ 34.77$ 38.22$ 71.97
Weighted average shares outstanding - basic (in shares)106.7107.1105.7
Weighted average shares outstanding - diluted (in shares)113.7113.5112.2
Statements of Comprehensive Income   
Net income$ 3,953.6$ 4,338.4$ 8,075.3
Other comprehensive income (loss), net of tax:   
Unrealized gain (loss) on debt securities158.2(213.6)(56.4)
Loss on foreign currency translation(0.3)0.00.0
Unrealized gain on cash flow hedges0.01.00.9
Comprehensive income4,111.54,125.88,019.8
Net product sales   
Revenues:   
Revenue from contract with customer7,078.06,893.712,117.2
Expenses:   
Cost of goods sold and of collaboration and contract manufacturing932.1800.01,773.1
Collaboration revenue   
Revenues:   
Revenue from contract with customer5,503.14,914.13,673.3
Other revenue   
Revenues:   
Revenue from contract with customer536.1365.1281.2
Cost of collaboration and contract manufacturing   
Expenses:   
Cost of goods sold and of collaboration and contract manufacturing$ 883.7$ 760.4$ 664.4

REGN Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
shares in Millions, $ in Millions
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 2,730.0$ 3,105.9
Marketable securities8,114.84,636.4
Accounts receivable, net5,667.35,328.7
Inventories2,580.52,401.9
Prepaid expenses and other current assets386.6411.2
Total current assets19,479.215,884.1
Marketable securities5,396.56,591.8
Property, plant, and equipment, net4,146.43,763.0
Intangible assets, net1,038.6915.5
Deferred tax assets2,575.41,723.7
Other noncurrent assets444.1336.4
Total assets33,080.229,214.5
Current liabilities:  
Accounts payable606.6589.2
Accrued expenses and other current liabilities2,357.92,074.2
Deferred revenue458.9477.9
Total current liabilities3,423.43,141.3
Long-term debt1,982.91,981.4
Finance lease liabilities720.0720.0
Deferred revenue126.769.8
Other noncurrent liabilities854.1638.0
Total liabilities7,107.16,550.5
Commitments and contingencies
Stockholders' equity:  
Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none0.00.0
Additional paid-in capital11,354.09,949.3
Retained earnings27,260.323,306.7
Accumulated other comprehensive loss(80.9)(238.8)
Treasury Stock, at cost; 25.5 shares in 2023 and 22.6 shares in 2022(12,560.4)(10,353.3)
Total stockholders' equity25,973.122,664.0
Total liabilities and stockholders' equity33,080.229,214.5
Class A Stock  
Stockholders' equity:  
Common stock$ 0.0$ 0.0
Common Stock, shares issued (in shares)1.81.8
Common Stock  
Stockholders' equity:  
Common stock$ 0.1$ 0.1
Common Stock, shares issued (in shares)133.1130.4
REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
 CEO
 WEBSITEwww.regeneron.com
 EMPLOYEES12256

Regeneron Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Regeneron Pharmaceuticals Inc? What does REGN stand for in stocks?

REGN is the stock ticker symbol of Regeneron Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Regeneron Pharmaceuticals Inc (REGN)?

As of Fri Feb 23 2024, market cap of Regeneron Pharmaceuticals Inc is 104.23 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of REGN stock?

You can check REGN's fair value in chart for subscribers.

What is the fair value of REGN stock?

You can check REGN's fair value in chart for subscribers. The fair value of Regeneron Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Regeneron Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for REGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Regeneron Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether REGN is over valued or under valued. Whether Regeneron Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Regeneron Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for REGN.

What is Regeneron Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Feb 23 2024, REGN's PE ratio (Price to Earnings) is 26.36 and Price to Sales (PS) ratio is 7.95. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. REGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Regeneron Pharmaceuticals Inc's stock?

In the past 10 years, Regeneron Pharmaceuticals Inc has provided 0.113 (multiply by 100 for percentage) rate of return.